Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2025 · 85 positions · Total reported value $1.34B · Top-10 concentration 50.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, Eversept Partners, LP disclosed 85 equity positions with a combined reported value of $1.34B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were QQQ ($138.09M), GSK ($91.52M), NTRA ($83.65M). By sector, the heaviest allocations are Health Care 77.1%, Industrials 6.6%. Versus the prior quarter, allocation shifted toward Other (+3.4pp), Health Care (+1.8pp) and away from Consumer Discretionary (-1.1pp), Industrials (-4.0pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q3 2025 were QURE ($51.21M), ABVX ($36.21M), PODD ($14.08M).

Of the 27 positions fully exited versus the prior quarter, the largest were INSP ($21.34M), IQV ($15.38M), PTGX ($15.33M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • QURE UNIQURE NV · $51.21M
  • ABVX ABIVAX SA · $36.21M
  • PODD INSULET CORP · $14.08M
  • RNAM AVIDITY BIOSCIENCES INC · $13.20M
  • NVO NOVO-NORDISK A S · $12.08M
  • SPRY ARS PHARMACEUTICALS INC · $9.81M
  • BMRN BIOMARIN PHARMACEUTICAL INC · $7.94M
  • ARDX ARDELYX INC · $7.88M

Fully Exited (vs previous quarter)

  • INSP INSPIRE MED SYS INC COM · prev qtr: $21.34M
  • IQV IQVIA HLDGS INC · prev qtr: $15.38M
  • PTGX PROTAGONIST THERAPEUTICS INC · prev qtr: $15.33M
  • GMED GLOBUS MED INC · prev qtr: $10.01M
  • TMO THERMO FISHER SCIENTIFIC INC · prev qtr: $5.55M
  • GKOS GLAUKOS CORP · prev qtr: $3.25M
  • AUTL AUTOLUS THERAPEUTICS LTD · prev qtr: $1.39M
  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $1.11M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 77.1%
Financials 0.0%
Other 16.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 230.00K $138.09M 10.27%
10.27%
Add
2 2.12M $91.52M 6.80%
6.80%
Reduce
3 519.64K $83.65M 6.22%
6.22%
Reduce
4 2.81M $81.60M 6.07%
6.07%
Add
5 3.47M $53.34M 3.97%
3.97%
Reduce
6 1.42M $51.22M 3.81%
3.81%
Add
7 877.37K $51.21M 3.81%
3.81%
New
8 111.70K $47.61M 3.54%
3.54%
Add
9 1.92M $41.53M 3.09%
3.09%
Add
10 2.08M $39.38M 2.93%
2.93%
Hold
11 426.50K $36.21M 2.69%
2.69%
New
12 538.66K $35.24M 2.62%
2.62%
Reduce
13 394.31K $34.56M 2.57%
2.57%
Reduce
14 1.42M $33.87M 2.52%
2.52%
Add
15 591.54K $32.91M 2.45%
2.45%
Add
16 1.15M $29.85M 2.22%
2.22%
Add
17 1.36M $27.55M 2.05%
2.05%
Add
18 687.13K $22.32M 1.66%
1.66%
Reduce
19 6.95M $22.31M 1.66%
1.66%
Add
20 62.82K $21.69M 1.61%
1.61%
Add
21 99.27K $19.68M 1.46%
1.46%
Add
22 12.60M $17.26M 1.28%
1.28%
Add
23 44.98K $14.53M 1.08%
1.08%
Add
24 45.60K $14.08M 1.05%
1.05%
New
25 105.09K $14.05M 1.04%
1.04%
Add
26 488.59K $13.90M 1.03%
1.03%
Add
27 302.91K $13.20M 0.98%
0.98%
New
28 217.71K $12.08M 0.90%
0.90%
New
29 123.67K $11.75M 0.87%
0.87%
Reduce
30 924.44K $11.54M 0.86%
0.86%
Reduce
31 486.02K $11.05M 0.82%
0.82%
Add
32 2.04M $10.97M 0.82%
0.82%
Add
33 1.37M $10.43M 0.78%
0.78%
Add
34 976.51K $9.81M 0.73%
0.73%
New
35 55.02K $9.63M 0.72%
0.72%
Reduce
36 16.72K $9.40M 0.70%
0.70%
Add
37 1.48M $9.06M 0.67%
0.67%
Add
38 502.23K $8.15M 0.61%
0.61%
Add
39 224.55K $8.01M 0.60%
0.60%
Reduce
40 146.64K $7.94M 0.59%
0.59%
New
41 1.43M $7.88M 0.59%
0.59%
New
42 51.77K $7.25M 0.54%
0.54%
New
43 350.81K $6.91M 0.51%
0.51%
New
44 693.53K $6.89M 0.51%
0.51%
Reduce
45 16.20K $6.79M 0.51%
0.51%
Reduce
46 14.43K $6.45M 0.48%
0.48%
New
47 392.44K $5.77M 0.43%
0.43%
Add
48 52.39K $4.96M 0.37%
0.37%
Reduce
49 166.39K $4.66M 0.35%
0.35%
Add
50 48.05K $4.52M 0.34%
0.34%
Reduce

FAQ

What did Eversept Partners, LP buy in 2025-Q3?

In its 2025-Q3 13F filing, Eversept Partners, LP reported 85 equity positions worth $1.34B in aggregate; its largest disclosed positions were QQQ ($138.09M), GSK ($91.52M), NTRA ($83.65M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.34B of long equity holdings across 85 positions as of 2025-Q3. Top-10 holdings account for 50.5% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →